| Acute graft versus host disease: a comprehensive review S Nassereddine, H Rafei, E Elbahesh, I Tabbara Anticancer research 37 (4), 1547-1555, 2017 | 232 | 2017 |
| Recent advances in the treatment of acute lymphoblastic leukemia H Rafei, HM Kantarjian, EJ Jabbour Leukemia & lymphoma, 2019 | 99 | 2019 |
| Allogeneic hematopoietic stem cell transplantation for GATA2 deficiency using a busulfan-based regimen M Parta, NN Shah, K Baird, H Rafei, KR Calvo, T Hughes, K Cole, ... Biology of Blood and Marrow Transplantation 24 (6), 1250-1259, 2018 | 87 | 2018 |
| Immune-based therapies for non-small cell lung cancer H Rafei, E El-Bahesh, A Finianos, S Nassereddine, I Tabbara Anticancer Research 37 (2), 377-387, 2017 | 85 | 2017 |
| Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity H Rafei, M Daher, K Rezvani British journal of haematology 193 (2), 216-230, 2021 | 73 | 2021 |
| KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape Y Li, R Basar, G Wang, E Liu, JS Moyes, L Li, LN Kerbauy, N Uprety, ... Nature medicine 28 (10), 2133-2144, 2022 | 58 | 2022 |
| Hereditary myeloid malignancies H Rafei, CD DiNardo Best Practice & Research Clinical Haematology 32 (2), 163-176, 2019 | 40 | 2019 |
| Microbiome-intestine cross talk during acute graft-versus-host disease H Rafei, RR Jenq Blood, The Journal of the American Society of Hematology 136 (4), 401-409, 2020 | 34 | 2020 |
| Third-party BK virus-specific cytotoxic T lymphocyte therapy for hemorrhagic cystitis following allotransplantation A Olson, R Lin, D Marin, H Rafei, MH Bdiwi, PF Thall, R Basar, ... Journal of Clinical Oncology 39 (24), 2710-2719, 2021 | 33 | 2021 |
| Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML NJ Short, H Rafei, N Daver, H Hwang, J Ning, JL Jorgensen, TM Kadia, ... Blood Advances 4 (24), 6117-6126, 2020 | 31 | 2020 |
| Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia H Rafei, HM Kantarjian, EJ Jabbour British Journal of Haematology 188 (2), 207-223, 2020 | 28 | 2020 |
| Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering L Li, V Mohanty, J Dou, Y Huang, PP Banerjee, Q Miao, JG Lohr, ... Science Advances 9 (30), eadd6997, 2023 | 25 | 2023 |
| Prevalence of EGFR and ALK mutations in lung adenocarcinomas in the Levant Area-a prospective analysis A Tfayli, H Rafei, A Mina, M Khalil, N Fakhreddin, R Mahfouz, S Hamouri, ... Asian Pacific journal of cancer prevention: APJCP 18 (1), 107, 2017 | 24 | 2017 |
| Outcome of patients with double-expressor lymphomas (DELs) treated with R-CHOP or R-EPOCH A Aggarwal, H Rafei, F Alakeel, AN Finianos, ML Liu, E El-Bahesh, ... Blood 128 (22), 5396, 2016 | 24 | 2016 |
| Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial D Marin, Y Li, R Basar, H Rafei, M Daher, J Dou, V Mohanty, M Dede, ... Nature Medicine, 1-13, 2024 | 23 | 2024 |
| A critical appraisal of extracorporeal photopheresis as a treatment modality for acute and chronic graft-versus-host disease H Rafei, M A. Kharfan-Dabaja, T Nishihori Biomedicines 5 (4), 60, 2017 | 18 | 2017 |
| Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive … C Saberian, N Abdel-Wahab, A Abudayyeh, H Rafei, J Joseph, G Rondon, ... Journal for immunotherapy of cancer 9 (2), 2021 | 15 | 2021 |
| Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies H Rafei, MA Kharfan-Dabaja Hematology/oncology and stem cell therapy 11 (1), 1-12, 2018 | 15 | 2018 |
| Pleurodesis in malignant pleural effusions: outcome and predictors of success H Rafei, S Jabak, A Mina, A Tfayli Integr Cancer Sci Therap 2 (5), 216-221, 2015 | 14 | 2015 |
| Targeting advanced urothelial carcinoma-developing strategies O Alhalabi, H Rafei, A Shah, A Siefker-Radtke, M Campbell, J Gao Current opinion in oncology 31 (3), 207-215, 2019 | 13 | 2019 |
